IVPH -- INNOVIVE Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVPH -- INNOVIVE Pharmaceuticals

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (9)	9/12/2007 5:22:25 PM
From: tuck	of 117

IP check might not be easy . . . check this from 2004: >>Drugs R D. 2004;5(6):359-62. Tamibarotene: AM 80, retinobenzoic acid, Tamibaro. [No authors listed] Tamibarotene [AM 80, retinobenzoic acid, Amnoid, Tamibaro] is a novel synthetic retinoid that is in development with Nippon Shinyaku as a potential treatment for acute promyelocytic leukaemia (APL) and is pending approval in Japan. Tamibarotene was being developed by Shionogi in Japan but the company subsequently discontinued its involvement. Various nonindustrial sources, such as the University of Tokyo, Japan, have also played a role in the development of tamibarotene.Nippon Shinyaku has licensed the rights to tamibarotene from Toko Pharmaceutical Industries for the treatment of acute promyelocytic leukaemia, according to Nippon Shinyaku's June 2004 pipeline update. However it is unclear when Toko Pharmaceutical Industries acquired rights to the compound.<< Which is interesting, because of course, Nippon Shinyaku is where IVPH got INNO-406. So who are these TMRC guys IVPH is dealing with now? Details are sketchy: tmrc.co.jp Doesn't show how they got tamibarotene. I just tried searching japanese patent apps. Couldn't figure out how. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next